It is stimulant-free by not containing caffeine
Extended 20-week titration Slower, more gradual protocol: Weeks 1-6: 0.6mg weekly (extended from 4 weeks) Weeks 7-12: 1.2mg weekly (6 weeks at this dose) Weeks 13-18: 1.8mg weekly (6 weeks) Week 19+: 2.4mg weekly OR stay at 1.8-2.0mg Advantages: Significantly reduced nausea Better long-term adherence More comfortable adaptation Lower dropout risk Trade-offs: Slower initial weight loss Takes longer to reach maximum efficacy More weeks of injections to get to target Similar total weight loss (just slower progression) Lower maintenance doses Alternative endpoint options: 1.8mg weekly maintenance: ~9% average weight loss (vs 10% at 2.4mg) Notably better tolerated Fewer ongoing side effects 25% cost savings Many find this sufficient 2.0mg weekly maintenance: ~9.5% average weight loss Middle ground approach Good efficacy, good tolerance Slight cost savings Recommended trial first When to choose lower maintenance: Achieved satisfactory weight loss before reaching 2.4mg Significant nausea at 2.4mg Budget constraints (research peptides expensive) Prefer comfort over maximum results Already combining with semaglutide (lower cagrilintide dose acceptable) Managing breakthrough nausea during titration First-line interventions: Pause escalation (stay at current dose 1-2 extra weeks) Ginger supplementation (500-1,000mg before meals) Smaller, more frequent meals (5-6 per day) Avoid trigger foods (fatty, spicy, fried) Stay upright 2 hours after eating Second-line strategies: Vitamin B6 (25-50mg daily) Sea-Bands acupressure wristbands Cold foods vs hot (better tolerated) Liquid nutrition if solids difficult (protein shakes) Medication options: Zofran/ondansetron (most effective, prescription) Promethazine (prescription) Meclizine/Dramamine (OTC, less effective) When to reduce dose: Nausea interfering with daily life Unable to eat adequate protein Vomiting more than occasionally Preference for slower approach SeekPeptides helps you optimize your titration based on real-time side effects
Wounds 16 , 274283 (2017)
But its stimulation of melanocyte proliferation raises theoretical concerns, and case reports of melanoma in users have been published
GLP-1 and GIP therapy should be considered in people with indicators of high risk or established atherosclerotic cardiovascular disease (ASCVD)
The result is expressed as the number of correct responses divided by the total number of stimulations
